{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-103526","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.587076+00:00","generated_at":"2026-05-17T19:32:50.788825+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Q32 Bio Q2 2025 net loss $9.5M ($0.78/sh); cash $54.8M, runway into 2027","bullets":["Net loss $9.5M ($0.78 per share) vs $17.0M ($1.42) a year ago; R&D expenses fell to $5.2M from $13.4M.","Cash and equivalents $54.8M at June 30, 2025, expected to fund operations into 2027.","SIGNAL-AA Part B topline data readout on track for 1H 2026; Part A OLE dosing ongoing.","Fast Track designation granted by FDA for bempikibart in alopecia areata.","Appointed Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-103526","json":"https://secwatch.observer/filing/0000950170-25-103526.json","markdown":"https://secwatch.observer/filing/0000950170-25-103526.md","text":"https://secwatch.observer/filing/0000950170-25-103526.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000095017025103526/0000950170-25-103526-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000095017025103526/qttb-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:32:50.788825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}